Tavlesse® (fostamatinib)

Tavlesse® is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments

Thromboembolic Risk in ITP

Watch

Tavlesse® (fostamatinib)
Mechanism of Action

Watch

ITP: Immune thrombocytopenia

UK-TVLS-2600011 | Date of Preparation: June 2026